Medpace Holdings
Price
Price
Frequently asked questions
What is Medpace Holdings's market capitalization?
What is Medpace Holdings's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Medpace Holdings?
What are the analyst ratings and target price for Medpace Holdings's stock?
What is Medpace Holdings's revenue over the trailing twelve months?
What is the EBITDA for Medpace Holdings?
What is the free cash flow of Medpace Holdings?
What is the 5-year beta of Medpace Holdings's stock?
How many employees does Medpace Holdings have, and what sector and industry does it belong to?
What is the free float of Medpace Holdings's shares?
Financials
Market Cap
$10.14B5Y beta
1.37EPS (TTM)
$11.42Free Float
25.56MP/E ratio (TTM)
28.55Revenue (TTM)
$2.07BEBITDA (TTM)
$437.53MFree Cashflow (TTM)
$535.65MPricing
Analyst Ratings
The price target is $447.43 and the stock is covered by 7 analysts.
Buy
5
Hold
2
Sell
0
Information
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
5,900
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker